Uncategorized
Phase 3 results show InSite drugs unable to fully resolve blepharitis
InSite Vision Inc. has announced top-line clinical results from its DOUBle phase 3 clinical trials for the treatment of moderate-to-severe blepharitis, according to a company press release. The drugs under evaluation, AzaSite Plus (azithromycin 1%, dexamethasone 0.1%) and DexaSite (polycarbophil, edetate disodium, sodium chloride, dexamethasone 0.1%), did not meet the primary endpoint of complete resolution of all clinical signs and symptoms of blepharitis, the release said.They did, however, demonstrate statistically significant improvements in the clinical signs and symptoms at day 15.